This VJHemOnc podcast explores how BTK inhibitor therapy can be personalized for patients with chronic lymphocytic leukemia (CLL), considering disease biology, patient characteristics and treatment goals.

Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses frontline treatment selection, molecular risk and factors influencing BTK inhibitor choice, while Florian Simon, MD, University Hospital Cologne, Cologne, Germany, examines cardiovascular toxicity and treatment considerations in older patients and those with comorbidities. Dima El-Sharkawi, MB, BS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, discusses quality of life and shared decision-making, and Gianluca Gaidano, MD, PhD, University of Eastern Piedmont, Vercelli, Italy, explores BTK inhibitor selectivity, safety and treatment options following covalent BTK inhibitor failure.

In this episode of the VJHemOnc podcast, leading experts discuss key advances in multiple myeloma presented at the 23rd Annual Meeting and Exposition of the International Myeloma Society (IMS 2026), held in Glasgow, UK. Pieter Sonneveld reviews long-term progression-free survival outcomes from the Phase III PERSEUS trial (NCT03710603), while Zachary Avigan explores the potential for treatment cessation in patients with sustained measurable residual disease (MRD) negativity and the evolving concept of cure. Rakesh Popat discusses emerging combination strategies at first relapse, and Luciano Costa examines the survival benefits of teclistamab plus daratumumab in the Phase III MajesTEC-3 trial (NCT05083169). Hermann Einsele highlights real-world and long-term outcomes with ciltacabtagene autoleucel (cilta-cel), Shaji Kumar discusses the Phase III CERVINO trial of etentamig, and Paul Richardson explores the evolving role of cereblon E3 ligase modulators (CELMoDs). Together, these experts consider how advances in immunotherapy, novel agents, and treatment sequencing may shape the future management of patients with multiple myeloma.

This episode of the VJHemOnc podcast features an exclusive expert-led roundtable discussion summarizing two sessions from the 8th International Workshop on Acute Leukemias (iwAL 2026) that focused on novel targets, combinations, and treatments in acute myeloid leukemia (AML). This session is chaired by Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, who is joined by panelists Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France. The experts explore the evolving genetic classification of AML and the nuances of TP53, the move from azacitidine and venetoclax toward molecularly guided triplets, emerging strategies to overcome menin inhibitor resistance and target TP53-mutated disease, and the promise of an all-oral regimen in this malignancy.

This episode of the VJHemOnc podcast, featuring Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, focuses on the practical use of BTK inhibitors (BTKis) in non-Hodgkin lymphoma (NHL). Dr Kamdar begins by discussing which factors guide patient selection for BTKi therapy and outlines how to choose among available agents. She then shares valuable insights on toxicity management, approaching patients with cardiovascular comorbidities, and monitoring treatment response and progression. Finally, Dr Kamdar leaves community physicians with three practical takeaways for successfully using BTKis in everyday clinical practice.

This VJHemOnc podcast explores the evolving role of gene therapy in hemophilia, focusing on the challenges of AAV-based approaches and the development of next-generation strategies.

Radek Kaczmarek, PhD, Indiana University School of Medicine, Indianapolis, IN, discusses the limitations of AAV gene therapy in hemophilia A, including factor VIII engineering, durability, and liver toxicity. He also examines potential malignancy risks associated with AAV integration and the importance of long-term surveillance following treatment. Finally, Dr Kaczmarek discusses emerging non-AAV approaches, including lentiviral gene therapy, targeted gene insertion, and gene editing, and their potential to address some of the limitations of current gene therapy approaches.

This VJHemOnc podcast explores the evolving management of mantle cell lymphoma (MCL), from assessing patient fitness to sequencing therapy after BTK inhibitor progression. Tycel Phillips, MD, FASCO, City of Hope, Duarte, CA, and Yasmin Karimi, MD, University of Michigan, Ann Arbor, MI, discuss assessing fitness and frailty, while Craig Portell, MD, University of Virginia, Charlottesville, VA, outlines the multidisciplinary approach to MCL care. Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, reviews frontline sequencing, including using MRD status to guide transplant decisions, and Dr Phillips and Dr Portell discuss managing patients with higher-risk disease features. Dr Portell also addresses toxicity and treatment burden with long-term BTK inhibitor use. To conclude, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, and Dr Karimi highlight emerging options after BTK inhibitor progression, including non-covalent BTK inhibitors, BCL2 inhibitors, CAR T-cell therapy, and bispecific antibodies.

This VJHemOnc podcast explores the evolving treatment landscape in multiple myeloma, focusing on treatment selection and sequencing across the disease course. Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses shared decision-making in frontline treatment, while Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, explores sequencing CAR T-cell therapies and bispecific antibodies, including the choice between BCMA- and GPRC5D-directed approaches. Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, reviews updated findings from the MajesTEC-3 trial (NCT05083169) of teclistamab plus daratumumab in high-risk disease, and Peter Voorhees discusses Phase III MonumenTAL-3 (NCT05455320) data evaluating talquetamab plus daratumumab, with or without pomalidomide. Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, highlights strategies for managing infections associated with bispecific antibodies, while Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the transition towards community-based delivery of bispecific therapies.

There has been a significant shift in the treatment of acute lymphoblastic leukemia (ALL), driven by the emergence of novel immunotherapies. In this episode, leading experts explore how these advances are changing the treatment landscape and where the field is headed next. First, Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, outlines emerging treatment strategies for ALL and highlights the potential to reduce reliance on intensive chemotherapy by integrating novel therapies into clinical practice. Then, Martin Schrappe, MD, FRCP, University Medical Center Schleswig-Holstein, Kiel, Germany, shares insights into a trial evaluating blinatumomab as a replacement for high-dose chemotherapy in pediatric patients with newly diagnosed high-risk ALL. Following this, you will hear a discussion from the 8th International Workshop on CAR-T and Bispecifics, in which Ibrahim Aldoss, MD, City of Hope, Duarte, CA, and Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, provide updates on T-cell engagers and CAR T-cell therapy in ALL. To conclude the episode, Nicola Maciocia, MBChB, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses advances in CAR-T for T-cell ALL and comments on whether cellular immunotherapy may be the most promising approach to curing this leukemia subtype.